In ALK1510-c4 cells, Alectinib exposure at 1000 nM for 24 h transiently increased relative HER2 phosphorylation by ~25%. Exposure to Alectinib at 1000 nM for 9 days increased relative EGFR phosphorylation in ALK1510-c4 cells. In NCI-H2228 parental cells treated with Alectinib for 8 days, the cell viability IC50 was 219.6 nM. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Transient HER2 phosphorylation increase in ALK1510-c4 cells
Cell-based study · ALK1510-c4 cells [1]
ALK1510-c4 cells exposed to Alectinib at 1000 nM for 24 h showed a transient increase in relative HER2 phosphorylation of ~25%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1000 nM
- Exposure duration
- 24 h
- Method
- exposure
- Vehicle
- dimethyl sulfoxide (DMSO; Sigma-Aldrich)
Methods and source locations
Compound reported in the paper: Alectinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Drugs and reagents (S10); Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S120); Fig. 3 legend (S192)
Relative HER2 phosphorylation levels: Relative HER2 phosphorylation levels; comparator: nontreated controls — Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S120); Fig. 3 legend (S192)
Cell viability response in NCI-H2228 parental cells
Cell-based study · NCI-H2228 parental cells [2]
NCI-H2228 parental cells were treated with Alectinib for 8 days. The cell viability IC50 was 219.6 nM.
Literature-Reported Treatment Conditions
- Exposure duration
- for 8 days
- Method
- drugs were added
- Vehicle
- dimethyl sulfoxide
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: Alectinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > DTP cells escape ALK-TKI-induced cell death through activation of FGFR signaling (S10); Methods > Drugs and reagents (S108); Methods > Anti-cancer compound library screen of NCI-H2228 cells (S118); Methods > Cell proliferation assay (S122, S123, S124); Fig. 1 legend (S196)
cell viability: cell viability; comparator: vehicle — Results > DTP cells escape ALK-TKI-induced cell death through activation of FGFR signaling (S10); Methods > Cell proliferation assay (S123)
Increased relative EGFR phosphorylation in ALK1510-c4 cells
Cell-based study · ALK1510-c4 cells [1]
ALK1510-c4 cells were exposed to Alectinib at 1000 nM for 9 days. Relative EGFR phosphorylation, measured as phosphorylated EGFR divided by total EGFR, increased.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1000 nM
- Exposure duration
- 9 days
- Method
- exposure
- Vehicle
- dimethyl sulfoxide (DMSO; Sigma-Aldrich)
Methods and source locations
Compound reported in the paper: Alectinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Drugs and reagents (S10); Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S122, S124); Fig. 3 legend (S192)
relative phosphorylation (phosphorylated EGFR [pEGFR]/total EGFR): relative phosphorylation (phosphorylated EGFR [pEGFR]/total EGFR); comparator: nontreated controls — Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S122)